Outside of multiple sclerosis, Biogen researchers highlighted data from drugs in development for cancer, immunology and pain management. Biogen expects to have nine drugs in phase III trials by the second half of the year.Biogen shares closed Wednesday up 67 cents, or 1.3%, to $51.52.
Biogen Tries to Quell Fears About MS Drug Rivals
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts